Please assess the completion status of the following clinical trial:

Trial Title: Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent form;~* Men and women aged 45 to 74 (inclusive);~* Confirmed diagnosis of type 2 diabetes lasting for 1 year or more;~* Permanent scheme of therapy (without changing doses and drugs) by oral hypoglycemic drugs and / or insulin, long-term or ultra-long (adjustment of insulin dose is possible within 10% from baseline dose) and / or agonists of glucagon-like peptide-1 receptors (GLP-1) for at least 12 weeks before screening;~* HbA1c from 7.0 and not higher than 10.0%;~* BMI 22-40 kg / m2;~* Symptomatic distal sensorimotor diabetic polyneuropathy;~* Baseline TSS (Total Syptom Score) ˃5 points;~* Score ≥2 by at least one of the TSS symptoms;~* The severity of pain by the corresponding TSS subscale ≤ 2;~* NISLL (Neuropathy Impairment Score Low Limbs) ≥ 2 points;~* Patient consent to use adequate contraceptive methods for the entire study;~* Consent to maintain a stable diet, exercise, therapy and diabetes control throughout the study;~* Ability to comply with all protocol requirements.~Exclusion Criteria:~* Pregnant or lactating women, or women planning a pregnancy during a clinical trial;~* Type 1 diabetes and other specific types of diabetes;~* Acute metabolic complications of diabetes such as ketoacidosis or hyperosmolar state within 6 months prior to screening;~* Therapy with short and ultra-short insulin within 3 months before screening;~* Fasting plasma glucose at screening\> 15 mmol / l;~* The presence of severe complications of diabetes;~* Epilepsy, epileptiform seizures, head trauma with loss of consciousness, tumor, inflammatory and demyelinating diseases of the central nervous system;~* Diseases requiring prior or current treatment by systemic corticosteroid drugs, cytostatics or penicillamine;malignant neoplasms within the last 5 years (excluding basal cell carcinoma);~* Cardiovascular diseases in the stage of decompensation at present or within 3 months before screening;~* Uncontrolled arterial hypertension with systolic arterial pressure\> 180 mm Hg and diastolic blood pressure\> 110 mm Hg at screening;~* Nephrotic syndrome, severe chronic renal failure or significant kidney disease with a level of glomerular filtration rate (GFR) \<30 ml / min;~* Active viral (hepatitis B and C) or cirrhotic liver disease; increased aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) 3 times from upper normal limit; increased total bilirubin 2 times from upper normal limit;~* HIV; a severe infectious disease within 30 days before screening;~* Anemia (hemoglobin ≤ 105 g / l in women or ≤ 115 g / l in men); acute blood loss or donation of at least one unit of blood (500 ml) or blood transfusion within the previous 12 weeks;~* Drug or alcohol abuse;~* Intake of Cytoflavin® for 3 months before screening;~* Known allergies, hypersensitivity or contraindications to the drug Cytoflavin® or its components;~* Intake of alpha-lipoic acid, thiamine derivatives, pyridoxine, cyanocobalamin (excluding multivitamins), antidepressants and derivatives of gabapentin within 3 months before screening;~* Use of other investigational drugs within 3 months prior to screening;~* Inability to read or write; unwillingness to understand and follow protocol procedures; non-compliance with the protocol requirements.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Cytoflavin (Inosine + Nicotinamide + Riboflavin + Succinic Acid), 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml/min, for 10 days + Cytoflavin ((Inosine + Nicotinamide + Riboflavin + Succinic Acid), 2 tablets 2 times a day, for 75 days
- Group 2 (Type: PLACEBO_COMPARATOR): Placebo, 20 ml (two ampoules of 10 ml each) once a day intravenously in a dilution of 200 ml of 0.9% sodium chloride solution at a rate 3-4 ml / min, for 10 days + Placebo, 2 tablets 2 times a day, for 75 days

Based on this trial design, predict the completion outcome and termination type (if applicable).